The Growth Opportunities Under Your Nose

Hot-shot growth stocks aren’t the only way to get decent capital returns…

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m generally rubbish at spotting small companies that are on the fast track to heady growth.
 
For proof, look no further than my decision in November 2013 that butchers’ shop chain Crawshaw looked too expensive at 13p. As I write, the shares are at 63p, and the company’s growth prospects apparently look exciting enough to encourage the UK head of supermarket chain Lidl to jump ship and run the business.
 
Which isn’t to say, I hasten to add, that my own portfolio doesn’t have its share of companies exhibiting a decent rate of growth, even though I’m primarily an income investor.

Recovery stocks

Compass Group, for instance, up 95% in four years. GKN, up 146% over roughly the same period. And pasty shop chain Greggs, up 185% in just over two years.

All decent returns I think, and all fairly predictable at the time of purchase — although, as I’ve said before, I have been surprised at the actual extent of Greggs’ stellar rise.
 
Why ‘predictable’? Because the approach I take to looking for growth shares is largely one of looking for shares with recovery potential.
 
Put another way, while I’m rubbish at spotting businesses like Crawshaw’s, I reckon I’m much better at spotting unloved, out-of-favour businesses that have temporarily been hit by headwinds.

Contrarian picks

And as a strategy for finding growth shares, it’s one with some fairly weighty factual evidence on its side.
 
Well-known contrarian investor David Dreman, for instance, has conducted a number of in-depth studies into the long-term performance of various investment strategies.
 
And again and again, a strategy of buying those unloved, out-of-favour businesses — and holding them until they recover — delivers startling outperformance.
 
Put another way, load up on shares with price-earnings (P/E) ratios at below the market average, hold until they reach market average — and then sell, and buy another unloved, out-of-favour business.

Growth + Yield: win both ways

Of course, you don’t have to sell. I don’t. I like to buy unloved, out-of-favour businesses with a decent dividend yield, and simply hold them as income stocks.

And, let’s face it, when a business is hit by adverse headwinds, a low P/E and a high yield often go hand in hand.
 
Nor do you have to look too far to see investors who’ve profited from this ‘buy cheap, hold for the long term’ strategy.
 
Warren Buffett’s fabled purchase of Coca-Cola in the late 1980s, for instance, falls into exactly this category.

347% vs. 42%: take your pick

Or, for a UK example, take Neil Woodford, who is now heading his own investment firm, of course. As I’ve written before, in the 15 years to 31 December 2011, he delivered a 347% return, versus the FTSE All‑Share’s distinctly more modest 42%.
 
And underpinning Mr Woodford’s performance were a series of choice picks of — yes! — those unloved, out-of-favour businesses, bought when others couldn’t get out of them fast enough.
 
Behemoths British American Tobacco and Imperial Tobacco, for instance, bought back in the late 1990s and early 2000s, when the market was convinced that massive tobacco lawsuits lay around the corner.
 
Or GlaxoSmithKline and AstraZeneca, bought when the market was convinced that both businesses had run out of patentable drug discoveries.
 
As Mr Woodford himself told the Daily Telegraph not so long ago:

“The investment industry is full of pseudo‑scientific mumbo‑jumbo, which confuses investors. But what I do is actually quite simple and can be communicated simply: my job is to look for anomalies in the values put on companies by the stock market. Some companies are undervalued by the market, some are overvalued. A fund manager’s job is to find the former, and avoid the latter.

Ignore the naysayers

All of which sounds quite simple and straightforward. Except that it isn’t.
 
Because going against the crowd — which is what contrarian investors do — is never comfortable. Simply put, you’re buying shares that everyone else is selling.
 
Moreover, just because a share is cheap, doesn’t mean that it won’t get cheaper still. So be prepared to stick to your guns and sit it out. Possibly for a lot longer than you’d expected.
 
And yet, the rewards are there.
 
As I said at the beginning: I’m rubbish at picking hot-shot growth stocks. But I like to think that I’m rather better at waiting for a generally well-managed business to recover from some temporary headwinds.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Malcolm owns shares in Compass, GKN, Greggs, GlaxoSmithKline, and AstraZeneca. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Surely, the Rolls-Royce share price can’t go any higher in 2025?

The Rolls-Royce share price was the best performer on the FTSE 100 in 2023 and so far in 2024. Dr…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Here’s how an investor could start buying shares with £100 in January

Our writer explains some of the things he thinks investors on a limited budget should consider before they start buying…

Read more »

Investing Articles

Forget FTSE 100 airlines! I think shares in this company offer better value to consider

Stephen Wright thinks value investors looking for shares to buy should include aircraft leasing company Aercap. But is now the…

Read more »

Investing Articles

Are Rolls-Royce shares undervalued heading into 2025?

As the new year approaches, Rolls-Royce shares are the top holding of a US fund recommended by Warren Buffett. But…

Read more »

Investing Articles

£20k in a high-interest savings account? It could be earning more passive income in stocks

Millions of us want a passive income, but a high-interest savings account might not be the best way to do…

Read more »

Investing Articles

3 tried and tested ways to earn passive income in 2025

Our writer examines the latest market trends and economic forecasts to uncover three great ways to earn passive income in…

Read more »

Investing Articles

Here’s what £10k invested in the FTSE 100 at the start of 2024 would be worth today

Last week's dip gives the wrong impression of the FTSE 100, which has had a pretty solid year once dividends…

Read more »

Investing Articles

UK REITs: a once-in-a-decade passive income opportunity?

As dividend yields hit 10-year highs, Stephen Wright thinks real estate investment trusts could be a great place to consider…

Read more »